2014至2023年接受丙型肝炎病毒治疗的人数及对新乙型肝炎和丁型肝炎疗法的适用经验
高收入国家治疗量较峰值下降41%,中低收入国家价格对扩大治疗可及性起重要作用。作者认为需加强主动筛查策略。
要点
- 高收入国家治疗量较峰值下降41%,报销是治疗的重要预测因素。
- 中低收入国家价格对通过公共和私立市场扩大治疗可及性起重要作用。
核心结论
- 过去10年,所有丙型肝炎病毒感染中21%接受了直接抗病毒药物治疗。
- 地区和时间的差异凸显了主动筛查策略的重要性。
- 若无项目增强,每个国家/地区接受治疗的丙型肝炎病毒感染者人数停滞,这可能不反映患病率较低,而可能反映现有策略的收益递减。
研究设计与样本
- 使用国家丙型肝炎病毒登记、已报告的直接抗病毒药物销售数据、制药公司报告和国家专家提供的估计,估算2014至2023年119个国家丙型肝炎病毒感染者的治疗人数。
- 对无可用数据的国家,采用相应全球疾病负担区域的平均估计值。
主要发现
- 估计13,816,000(95%不确定性区间:13,221,000-16,415,000)名丙型肝炎病毒感染者接受治疗,其中12,748,000(12,226,000-15,231,000)名使用直接抗病毒药物。
- 使用直接抗病毒药物者中11,081,000(10,542,000-13,338,000)名使用以索磷布韦为基础的直接抗病毒药物方案。
- 国家层面数据占这些估计的97%。
- 高收入国家治疗量较峰值下降41%,报销是治疗的重要预测因素。
- 中低收入国家价格对通过公共和私立市场扩大治疗可及性起重要作用,在埃及国家项目结束时的急剧下降后治疗继续缓慢增加。
临床怎么用
- 本研究可帮助医生和政策制定者理解相似地区或收入组内的治疗模式,并利用历史数据完善未来策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV). Monitoring HCV treatment trends by country, region, and globally is important to assess progress toward the World Health Organization's 2030 elimination targets. Additionally, historical patterns can help predict the uptake of future therapies for other liver diseases. METHODS: The number of people living with HCV (PLHCV) treated between 2014-2023 across 119 countries was estimated using national HCV registries, reported DAA sales data, pharmaceutical companies' reports, and estimates provided by national experts. For the countries with no available data, the average estimate of the corresponding Global Burden of Disease region was used. RESULTS: An estimated 13,816,000 (95% uncertainty intervals: 13,221,000-16,415,000) PLHCV were treated, of whom 12,748,000 (12,226,000-15,231,000) were treated with DAAs, of which 11,081,000 (10,542,000-13,338,000) were sofosbuvir-based DAA regimens. Country-level data accounted for 97% of these estimates. In high-income countries, there was a 41% drop in treatment from its peak, and reimbursement was a large predictor of treatment. In low- and middle-income countries, price played an important role in expanding treatment access through the public and private markets, and treatment continues to increase slowly after a sharp drop at the end of the Egyptian national program. CONCLUSIONS: In the last 10 years, 21% of all HCV infections were treated with DAAs. Regional and temporal variations highlight the importance of active screening strategies. Without program enhancements, the number of treated PLHCV stalled in every country/region, which may not reflect a lower prevalence but may instead reflect the diminishing returns of existing strategies. IMPACT AND IMPLICATIONS: Long-term hepatitis C virus (HCV) infection can lead to cirrhosis and liver cancer. Since 2014, these infections can be effectively treated with 8-12 weeks of oral therapies. In 2015, the World Health Organization established targets to eliminate HCV by 2030, which included treatment targets for member countries. The current study examines HCV treatment patterns across 119 countries and regions from 2014 to 2023 to assess the impact of national programs. This study can assist physicians and policymakers in understanding treatment patterns within similar regions or income groups and in utilizing historical data to refine their strategies in the future.
引用
- Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies. J Hepatol. 2025. PMID: 39914746. doi:10.1016/j.jhep.2025.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。